newsAnti-VEGF therapyDiabetic Macular Edema
FAc Intravitreal Implant Achieves Comparable Visual Outcomes with 53% Fewer Injections in Diabetic Macular Edema: Phase 4 NEW DAY Study
By MedXY|Apr 2, 2026
The Phase 4 NEW DAY study demonstrates that fluocinolone acetonide (FAc) 0.19 mg implant as baseline therapy achieves similar visual acuity and anatomical improvements compared to aflibercept in diabetic macular edema patients, while signif
